Text Size

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00161668
First received: September 8, 2005
Last updated: March 14, 2007
Last verified: March 2007
History of Changes
  Purpose

This study is designed to assess the safety of Mylotarg therapy in routine practice.


Condition Intervention Phase
Acute Myeloid Leukemia
 Drug: Mylotarg
 Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment: 500
Study Start Date: October 2001
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Treated by Mylotarg
  • Provide ICF
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00161668

  Show 59 Study Locations
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00161668     History of Changes
Other Study ID Numbers: 0903X-100847
Study First Received: September 8, 2005
Last Updated: March 14, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Leukemia, Myeloid
Neoplasms by Histologic Type
Neoplasms
 Gemtuzumab
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013